scholarly journals Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

2019 ◽  
Vol 3 (20) ◽  
pp. 3132-3135 ◽  
Author(s):  
Manali Kamdar ◽  
Hongli Li ◽  
Robert W. Chen ◽  
Lisa M. Rimsza ◽  
Michael L. Leblanc ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Similar Efficacy ◽  
Key Points ◽  
Mantle Cell

Key Points Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.

scholarly journals Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Blood ◽  
2018 ◽  
Vol 132 (19) ◽  
pp. 2016-2025 ◽  
Author(s):  
Jia Ruan ◽  
Peter Martin ◽  
Paul Christos ◽  
Leandro Cerchietti ◽  
Wayne Tam ◽  
...  
Keyword(s):  
Adverse Events ◽  
Maintenance Therapy ◽  
Mantle Cell Lymphoma ◽  
Initial Treatment ◽  
Cell Lymphoma ◽  
Chronic Therapy ◽  
Key Points ◽  
Mantle Cell

Key Points Lenalidomide plus rituximab as induction and maintenance therapy for MCL can achieve durable MRD-negative complete remissions. Chronic therapy–associated adverse events are generally nonaccumulative and remain manageable.

scholarly journals Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Blood ◽  
2014 ◽  
Vol 123 (11) ◽  
pp. 1665-1673 ◽  
Author(s):  
Julie E. Chang ◽  
Hailun Li ◽  
Mitchell R. Smith ◽  
Randy D. Gascoyne ◽  
Elisabeth M. Paietta ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Eastern Cooperative Oncology Group ◽  
Phase 2 ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Phase 2 Study ◽  
Key Points ◽  
Mantle Cell

Key Points VcR-CVAD produced high overall and CR rates in previously untreated MCL patients. No substantial difference in 3-year PFS or OS was observed in patients receiving ASCT compared with patients receiving maintenance rituximab.

scholarly journals Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

2018 ◽  
Vol 182 (3) ◽  
pp. 404-411 ◽  
Author(s):  
Preetesh Jain ◽  
Jorge Romaguera ◽  
Samer A. Srour ◽  
Hun J. Lee ◽  
Frederick Hagemeister ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Cell Lymphoma ◽  
Phase Ii Clinical Trial ◽  
Mantle Cell

scholarly journals Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 ◽  
Vol 25 ◽  
pp. iii83-iii92 ◽  
Author(s):  
M. Dreyling ◽  
C. Geisler ◽  
O. Hermine ◽  
H.C. Kluin-Nelemans ◽  
S. Le Gouill ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Mantle Cell Lymphoma ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cell Lymphoma ◽  
Newly Diagnosed ◽  
Mantle Cell

scholarly journals High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Blood ◽  
2015 ◽  
Vol 126 (5) ◽  
pp. 604-611 ◽  
Author(s):  
Marie-Hélène Delfau-Larue ◽  
Wolfram Klapper ◽  
Françoise Berger ◽  
Fabrice Jardin ◽  
Josette Briere ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Standard Of Care ◽  
High Dose ◽  
Current Standard ◽  
Ki 67 ◽  
Key Points ◽  
Mantle Cell ◽  
High Dose Cytarabine

Key Points CDKN2A and TP53 deletions remain of bad prognostic value in younger MCL patients treated according to the current standard of care. CDKN2A and TP53 deletions have independent deleterious effects and should be considered for treatment decisions in addition to MIPI and Ki-67 index.

scholarly journals TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Blood ◽  
2017 ◽  
Vol 130 (17) ◽  
pp. 1903-1910 ◽  
Author(s):  
Christian W. Eskelund ◽  
Christina Dahl ◽  
Jakob W. Hansen ◽  
Maj Westman ◽  
Arne Kolstad ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Standard Of Care ◽  
Younger Patients ◽  
Tp53 Mutations ◽  
Key Points ◽  
Mantle Cell ◽  
Frontline Treatment

Key Points The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.

scholarly journals First experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the TP53 gene

2020 ◽  
Vol 65 (4) ◽  
pp. 483-500
Author(s):  
D. A. Koroleva ◽  
N. G. Gabeeva ◽  
M. Yu. Drokov ◽  
V. A. Vasilyeva ◽  
B. V. Biderman ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Chronic Gvhd ◽  
Tp53 Gene ◽  
Adverse Outcomes ◽  
Haematopoietic Stem Cell ◽  
Mantle Cell ◽  
Unrelated Donors ◽  
Stem Cells Transplantation

Introduction. Mutations in the TP53 gene in patients with mantle cell lymphoma (MCL TP53+) are associated with a low response to intensive chemotherapy (CT) and adverse outcomes. Allogeneic haematopoietic stem cells transplantation (allo-HSCT) is a curative approach in MCL-TP53+ patients.Aim. Efficacy and safety assessment of allo-HSCT in MCL-TP53+ patients.Main findings. During 2016–2020, allo-HSCT in MCL TP53+ was performed in three patients. Two of them were grafted from HLA-identical unrelated donors, and one — from a haploidentical donor. Pre-transplant conditioning was “fludarabine + treosulfan + melphalan” in one case, and “fludarabine + busulfan” — in the other two. In three patients, leukocyte and platelet counts were recovered at days +18 and +20, +17 and +21, +19 and +16 after allo-HSCT, respectively. Acute graft-versushost disease (aGVHD) was observed in all patients (grade I — in 2 patients, grade IV — in 1 patient). One patient developed chronic GVHD (cGVHD) of moderate grade. All three patients exhibited complete remission and 100% donor chimerism in allo-HSCT follow-up of 6, 15 and 40 months, respectively.

Sign in / Sign up

Export Citation Format

Share Document